Advertisement
Canada markets closed
  • S&P/TSX

    21,942.16
    +148.26 (+0.68%)
     
  • S&P 500

    5,482.87
    +4.97 (+0.09%)
     
  • DOW

    39,164.06
    +36.26 (+0.09%)
     
  • CAD/USD

    0.7300
    -0.0001 (-0.01%)
     
  • CRUDE OIL

    81.88
    +0.14 (+0.17%)
     
  • Bitcoin CAD

    84,391.41
    +1,090.88 (+1.31%)
     
  • CMC Crypto 200

    1,283.06
    +16.91 (+1.34%)
     
  • GOLD FUTURES

    2,338.10
    +1.50 (+0.06%)
     
  • RUSSELL 2000

    2,038.34
    +20.22 (+1.00%)
     
  • 10-Yr Bond

    4.2880
    -0.0280 (-0.65%)
     
  • NASDAQ futures

    20,094.75
    +55.25 (+0.28%)
     
  • VOLATILITY

    12.24
    -0.31 (-2.47%)
     
  • FTSE

    8,179.68
    -45.65 (-0.55%)
     
  • NIKKEI 225

    39,341.54
    -325.53 (-0.82%)
     
  • CAD/EUR

    0.6814
    -0.0003 (-0.04%)
     

Aurora Cannabis Full Year 2024 Earnings: CA$1.28 loss per share (vs CA$8.22 loss in FY 2023)

Aurora Cannabis (TSE:ACB) Full Year 2024 Results

Key Financial Results

  • Revenue: CA$270.3m (up 16% from FY 2023).

  • Net loss: CA$55.3m (loss narrowed by 79% from FY 2023).

  • CA$1.28 loss per share (improved from CA$8.22 loss in FY 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Aurora Cannabis Earnings Insights

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada.

Performance of the Canadian Pharmaceuticals industry.

The company's shares are down 11% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 2 warning signs for Aurora Cannabis that you need to be mindful of.

ADVERTISEMENT

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com